Involving Avidin-biotin Binding Patents (Class 435/7.5)
-
Patent number: 7754439Abstract: Methods for forming cell arrays of multiple cell samples arranged substantially in a monolayer on a single substrate particularly suited for diagnostic analysis are disclosed. The cell arrays are formed with a high-speed dispensing apparatus capable of dispensing small volumes in precise, complex patterns. Also disclosed are substrates upon which cell arrays may be formed, and methods for conducting diagnostic analyses on the formed cell arrays.Type: GrantFiled: June 10, 2004Date of Patent: July 13, 2010Assignees: Accupath Diagnostic Laboratories, Inc., Biodot, Inc.Inventors: Mathew Moore, Miriam Reyes, David Baunoch, Thomas Tisone, Brendan O'Farrell
-
Patent number: 7754442Abstract: A reagent kit that is used for determining a characteristic of tissue obtained from a patient is described. The reagent kit comprising expression measurement reagents for measuring expression level of cyclin-dependant kinase (CDK) and activity measurement reagents for measuring activity value of CDK. The expression measurement reagents comprise first reagents and second reagents, and the activity measurement reagents comprise third reagents and fourth reagents. In the reagent kit, a first reagent set of the first and third reagents is stored under a first storage condition relating to temperature, and a second reagent set of the second and fourth reagents is stored under a second storage condition relating to temperature.Type: GrantFiled: September 29, 2006Date of Patent: July 13, 2010Assignee: Sysmex CorporationInventors: Hideki Ishihara, Satoshi Nakayama, Yuko Kawasaki, Aya Katayama
-
Patent number: 7745162Abstract: The invention provides compositions and methods for measuring human serum hepcidin levels. The invention provides methods for the oxidative refolding of a hepcidin polypeptide to a form that is mature, bioactive and folded as in the native configuration and molecular mass; a method for measuring the level of native, bioactive hepcidin in a vertebrate animal.Type: GrantFiled: November 11, 2008Date of Patent: June 29, 2010Assignee: Intrinsic LifesciencesInventors: Xavier Lauth, Mark E. Westerman, Vaughn E. Ostland, Jason A. Stannard, Michael W. Pennington
-
Patent number: 7745569Abstract: Phage peptide display technology was used to identify peptides that bind specifically to the amyloid form of the A?1-40 peptide. Peptides with similar structural features and bind to the amyloid form of A?1-40 but not to monomeric A?1-40, are provided. Such peptides are useful as carrier molecules to deliver therapeutic and diagnostic reagents to amyloid plaques.Type: GrantFiled: April 7, 2004Date of Patent: June 29, 2010Assignee: The Regents of the University of CaliforniaInventor: Paul Taylor Martin
-
Publication number: 20100143941Abstract: This invention provides devices and methods for detecting an analyte suspected to be present in a sample. The subject devices and methods are particularly useful for performing immunoassays on a variety of analyte, especially those present in a bodily fluid.Type: ApplicationFiled: March 17, 2008Publication date: June 10, 2010Inventors: Xin Wu, Fuquan Zhao, Yinfel Wu, Fei Gao
-
Publication number: 20100130404Abstract: The invention provides compositions and methods for determining cardiodiabetes status in a subject. The invention also provides compositions and methods for treating a subject experiencing cardiodiabetes.Type: ApplicationFiled: July 17, 2009Publication date: May 27, 2010Inventors: Andreas PFUETZNER, Thomas Forst
-
Patent number: 7723063Abstract: The present invention concerns a method for the oxidative refolding of a hepcidin polypeptide to a form that is mature, bioactive and folded as in the native configuration and molecular mass; a method for measuring the level of native, bioactive hepcidin in a vertebrate animal; a method for measuring the level of hepcidin gene expression in a vertebrate animal; and a method for regulating the production of native, bioactive hepcidin in a vertebrate animal in vivo. The present invention also concerns an antibody or fragment thereof that specifically binds to a continuous, discontinuous, and/or conformational epitope of a mature and bioactive hepcidin folded as in the native configuration; and a pharmaceutical composition that includes the antibody or a hepcidin polypeptide and that provides antimicrobial, agonistic, or antagonistic activities in vivo in a vertebrate animal.Type: GrantFiled: April 28, 2005Date of Patent: May 25, 2010Assignee: Intrinsic LifesciencesInventors: Xavier Lauth, Mark E. Westerman, Vaughn E. Ostland, Jason A. Stannard, Michael W. Pennington
-
Patent number: 7718355Abstract: There is provided a method of detecting a pathogenic microorganism in real-time, using a modified flow-type surface plasmon resonance (SPR) biosensor, comprising the steps of: i) performing, in a batch-type, an immune reaction of a pathogenic microorganism and an antibody thereto; ii) selectively separating the pathogenic microorganism bound with the antibody; and iii) binding the pathogenic microorganism bound with the antibody on a surface of a chip of a flow-type SPR sensor system in real-time.Type: GrantFiled: December 28, 2006Date of Patent: May 18, 2010Assignee: Sungkyunkwan UniversityInventors: Sang-jun Sim, Chang-deok Kang
-
Publication number: 20100112558Abstract: The present invention relates to the field of methods and devices of miniaturized synthesis. More specifically, the present invention relates to the parallel synthesis of large number of different types of molecules and oligomers, such as oligonucleotides (oligos), peptides, lipids, carbohydrates, small ligand molecules, and other organic and inorganic molecules as probes for multiplexing assays. The probes may be synthesized from and/or attached to nanobeads to microbeads. The present invention provides for assays of multiplexing large scale biology, such as analysis of genomic DNAs and RNAs and proteomic proteins or peptides performed simultaneously on the synthetic beads.Type: ApplicationFiled: November 3, 2008Publication date: May 6, 2010Inventors: Xiaolian Gao, Xiaochuan Zhou
-
Publication number: 20100105077Abstract: The invention concerns multimers developed from recombinant proteins analogues of MHC class I.Type: ApplicationFiled: October 1, 2009Publication date: April 29, 2010Applicant: Institut Nationale De La Sante Et De La Recherche Medicale FranceInventors: François LANG, Marie Bodinier, François Davodeau, Marc Bonneville
-
Publication number: 20100099121Abstract: The present invention relates to a method for diagnosing cancers by measuring proteins associated with tumorigenesis and metastasis, and a diagnostic kit using the same, particularly relates to the method for diagnosing cancers by measuring the changes of glycosylation of proteins and the kit for diagnosis of cancers using the said method. The method and kit of the present invention can effectively be used for the sensitive diagnosis of cancers comprising colon cancer, stomach cancer, lung cancer and liver cancer.Type: ApplicationFiled: November 9, 2009Publication date: April 22, 2010Inventors: Jeong Heon Ko, Soo Young Hwang, Hosung Sohn, Sejeong Oh, Jeong Hwa Lee, Sang Chul Lee, Jong-Shin Yoo, Dae-Sil Lee
-
Publication number: 20100099120Abstract: It is intended to provide a method by which a substance having a phosphate group can be easily detected from a biological sample or the like, a method by which a phosphorylated amino acid residue is easily identified and a compound which can be used in the methods because of having a high coordinate bond forming capacity with a substance having a phosphate group.Type: ApplicationFiled: August 9, 2006Publication date: April 22, 2010Inventors: Tohru Koike, Veiji Kinoshita, Emiko Kinoshita
-
Publication number: 20100094560Abstract: The present invention provides methods, systems, and code for accurately classifying whether a sample from an individual is associated with irritable bowel syndrome (IBS). In particular, the present invention is useful for classifying a sample from an individual as an IBS sample using a statistical algorithm and/or empirical data. The present invention is also useful for ruling out one or more diseases or disorders that present with IBS-like symptoms and ruling in IBS using a combination of statistical algorithms and/or empirical data. Thus, the present invention provides an accurate diagnostic prediction of IBS and prognostic information useful for guiding treatment decisions.Type: ApplicationFiled: October 16, 2008Publication date: April 15, 2010Applicant: PROMETHEUS LABORATORIES INC.Inventors: AUGUSTO LOIS, BRUCE NERI
-
Publication number: 20100093623Abstract: Disclosed herein are compositions and methods relating to a peptide that inhibits Nod-like Receptors. Further provided are compositions and methods for treating or preventing inflammation, including diseases associated with inflammation such as inflammatory bowel disease, Crohn's disease, ulcerative colitis, arthritis, psoriasis, Alzheimer's disease, cardiovascular disease, diabetes, and sepsis.Type: ApplicationFiled: July 16, 2009Publication date: April 15, 2010Applicant: Burnham Institute for Medical ResearchInventors: John C. Reed, Benjamin Faustin, Arnold Satterthwait
-
Publication number: 20100086925Abstract: Exemplary embodiments relate to a microfluidic structure including: a plurality of sample chambers; a reaction chamber in which at least two types of materials, which respectively specifically react with at least two types of target materials, are immobilized; a detection chamber connected to the reaction chamber; a path connecting the chambers; and a valve for opening and closing the path, and a microfluidic device including the microfluidic structure. Since at least two types of materials specifically binding to target materials are immobilized in a reaction chamber of the microfluidic structure, space may be efficiently used and the target materials may be assayed in a one-step test. An internal space of the microfluidic device using the microfluidic structure, the amount of samples, and costs for manufacturing the microfluidic device may be reduced, and internal quality control may be efficiently performed using the microfluidic structure as a control for the operations.Type: ApplicationFiled: June 30, 2009Publication date: April 8, 2010Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: Jung Nam LEE, Beom Seok LEE, Kui Hyun KIM, Ji Won KIM
-
Publication number: 20100086945Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 25 and 49 of a hepcidin precursor protein, and quantifying the hepcidin precursor level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin.Type: ApplicationFiled: December 2, 2009Publication date: April 8, 2010Applicant: DRG International Inc.Inventors: Hasan Kulaksiz, Cyrill E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Publication number: 20100081148Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of hyaluronic acid can be used to determine whether a patient having suffered acute kidney injury will require long-term dialysis.Type: ApplicationFiled: September 23, 2009Publication date: April 1, 2010Inventors: Kai Singbartl, John A. Kellum, JR.
-
Patent number: 7682805Abstract: The invention relates to the use of Reelin as a marker for diagnosing psychiatric conditions. The disclosed tools and techniques can facilitate the diagnosis of psychiatric disorders including major depression, bipolar disorder, schizophrenia and autism.Type: GrantFiled: January 17, 2008Date of Patent: March 23, 2010Assignee: Regents of the University of MinnesotaInventor: S. Hossein Fatemi
-
Patent number: 7682806Abstract: The invention relates to the use of Reelin as a marker for diagnosing psychiatric conditions. The disclosed tools and techniques can facilitate the diagnosis of psychiatric disorders including major depression, bipolar disorder, schizophrenia and autism.Type: GrantFiled: January 17, 2008Date of Patent: March 23, 2010Assignee: Regents of the University of MinnesotaInventor: S. Hossein Fatemi
-
Publication number: 20100068696Abstract: The present invention relates to methods for detecting or quantifying an analyte in a test sample including providing at least one test mixture including a test sample, at least one marker complex, wherein each marker complex includes a particle, a marker, and one member of a coupling group, a first binding material selected to bind to a portion of the analyte, a second binding material selected to bind with a portion of the analyte other than the portion of the analyte for which the first binding material is selected, analyte analog, and/or marker conjugate. The at least one test mixture is passed through a membrane. The amount of marker on the membrane is detected and correlated to the presence or amount of analyte in the test sample.Type: ApplicationFiled: November 10, 2006Publication date: March 18, 2010Applicant: Cornell Research Foundation, Inc.Inventor: Antje J. Baeumner
-
Patent number: 7674766Abstract: The invention provides a method to C-terminally label proteins in a complex sample and identify those proteins, e.g., using mass spectrometry.Type: GrantFiled: February 11, 2005Date of Patent: March 9, 2010Assignee: Cornell Research Foundation, Inc.Inventor: Samie R. Jaffrey
-
Patent number: 7662572Abstract: The present invention relates to compounds, compositions, and methods in the field of detection of analytes. In particular to detection of viruses, cells, bacteria, lipid-membrane containing organisms, proteins, nucleic acids, carbohydrates and other biomolecules, organic molecules and inorganic molecules using a liquid crystal assay format.Type: GrantFiled: August 25, 2006Date of Patent: February 16, 2010Assignee: Platypus Technologies, LLC.Inventors: Nicholas Abbott, Christopher Murphy, Barbara Israel
-
Patent number: 7655427Abstract: The invention provides novel immunogenic proteins LigA and LigB from Leptospira for use in the development of effective vaccines and antibodies, as well as improved diagnostic methods and kits.Type: GrantFiled: April 8, 2005Date of Patent: February 2, 2010Assignee: Cornell Research Foundation, Inc.Inventors: Yung-Fu Chang, Raghavan U. M. Palaniappan
-
Publication number: 20100021496Abstract: The present invention relates to novel methods and compositions useful for detecting whole parathyroid hormone at a physiological level and C-terminal parathyroid fragments in a mammalian sample. Such detections may be useful to different parathyroid diseases or disorders in a subject, such as chronic renal failure, hyperparathyroidism and related bone diseases, from normal or non-disease states. One detects whole or non-fragmented (1 to 84) parathyroid hormone in a biological sample and optionally one or more of a selection of C-terminal parathyroid hormone peptide fragments that may or may not function as a parathyroid hormone antagonists. By either comparing values or using independently the value of either the one or more of a selection of C-terminal parathyroid hormone peptide fragments, the whole parathyroid hormone, or the combination of these values, one is able to differentiate chronic renal failure, parathyroid and bone related disease states, as well as differentiate such states from normal states.Type: ApplicationFiled: April 14, 2009Publication date: January 28, 2010Inventors: Thomas L. CANTOR, Zan W. Yang
-
Patent number: 7622261Abstract: The present invention relates to a method for diagnosing cancers by measuring proteins associated with tumorigenesis and metastasis, and a diagnostic kit using the same, particularly relates to the method for diagnosing cancers by measuring the changes of glycosylation of proteins and the kit for diagnosis of cancers using the said method. The method and kit of the present invention can effectively be used for the sensitive diagnosis of cancers comprising colon cancer, stomach cancer, lung cancer and liver cancer.Type: GrantFiled: December 28, 2002Date of Patent: November 24, 2009Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Jeong Heon Ko, Soo Young Hwang, Hosung Sohn, Sejeong Oh, Jeong Hwa Lee, Sang Chul Lee, Jong-Shin Yoo, Dae-Sil Lee
-
Publication number: 20090275052Abstract: A regulable molecular motor micropower biosensor comprises: a rotary motor, an optical energy conversion device, a signal molecular output device, a power resource system, a protective layer, a supporting material, and a bilayer lipid membrane fixing material. The molecular motor micropower biosensor is used for detecting biological macromolecules, viral molecules, etc.Type: ApplicationFiled: December 15, 2005Publication date: November 5, 2009Applicant: INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCESInventor: Jiachang Yue
-
Patent number: 7611853Abstract: Malarial parasite Plasmodium falciparum is responsible for the most severe form of malaria in humans, causing about 2 million deaths every year. Lack of effective vaccines and emergence of drug-resistant strains necessitate the need of novel drug targets to treat the disease. The present invention describes a novel assay method of identifying candidate compounds as anti-malarials based on the property of binding to plasmodial parasite 90 kDa heat shock protein.Type: GrantFiled: December 1, 2003Date of Patent: November 3, 2009Assignee: Indian Institute of ScienceInventors: Tatu Utpal, Pavithra Soundara Raghavan, Banumathy Gowrishankar
-
Patent number: 7604956Abstract: An assay exhibiting improved sensitivity for achieving a factor of ten times (10×) better sensitivity than current sensitivity levels achieved by prior-art immunoassays, as exemplified by ELISA. Three main implementations are described: IA/MPD, Super-ELISA and Reverse Geometry Immunoassay, including specific panel biomarker relationships for the early detection and recognition patterns of breast and prostate cancers. More sensitive immunoassays are achieved through a better understanding of sources of biological background, and by the rejection of particular sources thereof. Super-sensitive immunoassays permit measurement of blood sample biomarkers, and show distribution of low abundance proteins included relationships between cytokine non-Gaussian distributions, very large dynamic ranges and strong age dependence, and including new algorithms based on 2D correlations of studied biomarkers.Type: GrantFiled: February 25, 2005Date of Patent: October 20, 2009Assignee: BioTraces, Inc.Inventor: Andrzej J. Drukier
-
Patent number: 7598081Abstract: The subject invention provides new materials and methods for the efficient isolation and purification of stem cells. Specifically, conductive immunopolymers with stem cell specific antibodies can be used to remove stem cells from biological fluids.Type: GrantFiled: December 20, 2005Date of Patent: October 6, 2009Assignee: Morphogenesis, Inc.Inventors: Michael Lawman, Patricia Lawman
-
Patent number: 7598093Abstract: Embodiments of the present invention relate to devices and methods for detecting cellular products using detection particles having product-specific detection reagents and having a characteristic spectral feature. In particular, devices and methods are provided for measuring secreted cellular products including cytokines. Detection substrates, include microwells having product-specific capture reagents thereon or comprising hydrophobic membranes are described having greater capability to detect products from individual cells in a mixture of heterogeneous cells. With the use of multiple detection particles, multiple cellular products can be detected in a single well. Additionally, using the inherent spectral properties of detection particles, no enzymatic reactions are needed to visualize a secreted product, thereby increasing the sensitivity, reproducibility and ease of use.Type: GrantFiled: July 22, 2004Date of Patent: October 6, 2009Assignee: CTL Analyzers, LLCInventors: Paul V. Lehmann, Alexey Y. Karulin, Thomas Oliver Kleen
-
Patent number: 7579165Abstract: The present invention provides a method for effectively introducing sulfonic acid groups into the N-terminus of a protein or a peptide. The method comprises a modification step to react a N-terminus in a protein or peptide with a compound A which includes disulfide group and a cleavage step to cleave a disulfide bond of the disulfide group to convert into a sulfonic acid group. The present invention also provides a method of analyzing proteins or peptides easily and effectively on mass spectrometry and an intermediate that can be used to effectively derivatize proteins or peptides as sulfonic acid derivatives.Type: GrantFiled: October 13, 2004Date of Patent: August 25, 2009Assignee: Shimadzu CorporationInventors: Shigemi Norioka, Minoru Yamaguchi, Hiroki Kuyama, Takashi Obama, Eiji Ando, Takashi Nakazawa, Norikazu Ueyama, Taka-aki Okamura
-
Patent number: 7575874Abstract: This invention relates to the detection of fusion proteins. The invention provides a set of at least a first and a second molecular probe, each probe provided with a dye wherein the dyes together allow energy transfer, at least one probe provided with a reactive group allowing juxtaposing at least the first and second probes wherein the reactive group allows to modulate of juxtaposing the probes such that there is an increased likelihood of energy transfer between the dyes. A method is provided which permits detecting the presence of a fusion protein in a cell at the single cell level.Type: GrantFiled: May 5, 2005Date of Patent: August 18, 2009Assignee: Erasmus Universiteit RotterdamInventor: Jacobus Johannes Maria van Dongen
-
Patent number: 7572595Abstract: The present invention relates to a method for searching myelin using gonadotropin-releasing hormone receptors (GnRH-R) as a biomarker, more precisely, a method for investigating the distribution of myelin by immunohistochemical staining using GnRH-R antibody, based on the fact that GnRH-R and myelin are observed in the same region. The method for searching myelin of the invention can contribute to the studies on demyelination related degenerative brain disease and the disclosure of functions of myelin and the relation of myelin and GnRH-R.Type: GrantFiled: March 29, 2006Date of Patent: August 11, 2009Assignee: Korea Institute of Science and TechnologyInventors: Oh-Seung Kwon, Euna Park, Heesoo Pyo, Yong-Ho Huh
-
Patent number: 7572643Abstract: A microsphere for use in a bioassay comprising a glass core coated with a nanoparticle composite comprising a bioactive probe is provided. The nanoparticle composite coating enhances the density of bioprobe loading on the surface of the microspheres, resulting in enhanced dynamic range and sensitivity in bioassays. The particle may be used in detection systems where resonant light scattering properties of the particle are useful.Type: GrantFiled: November 21, 2005Date of Patent: August 11, 2009Assignee: E. I. du Pont de Nemours and CompanyInventors: Kevin Michael Croker, Michael B. Damore, Kostantinos Kourtakis, Michael P. Perry, James M. Prober, Paul Douglas Stull
-
Publication number: 20090176201Abstract: The present invention relates to methods, compositions and kits for affinity isolation, affinity purification and affinity assay based on microbubbles coated with an affinity molecule. Particularly, the invention provides protein microbubbles coated with an affinity molecule. In addition, the invention provides glass microbubbles coated with an affinity molecule. Methods of using the microbubbles of the invention for isolating analytes and cells are specifically provided.Type: ApplicationFiled: November 3, 2005Publication date: July 9, 2009Applicant: Iris Molecular Diagnostics, IncInventors: Edward Jablonski, Thomas Adams
-
Publication number: 20090176213Abstract: Reagents are disclosed for use in assays for analytes. The reagents are dry assay reagents that may be readily reconstituted for use in the assays. The dry assay reagents comprise a solid support and one or more molecules of a receptor immobilized on the solid support. The receptor comprises one or more binding sites for a ligand. A portion of a total number of the binding sites is bound to a conjugate comprising the ligand linked to a specific binding pair member and a portion of the total number of the binding sites is free. In use in an assay, a combination is provided in an aqueous medium comprising the sample and reagents for detecting the analyte wherein at least one of the reagents comprises the dry assay reagent mentioned above. The combination is incubated under conditions for binding of the analyte to one or more of the reagents.Type: ApplicationFiled: January 8, 2008Publication date: July 9, 2009Applicant: Siemens Healthcare Diagnostics Inc., a corporation of CaliforniaInventors: Yi Feng Zheng, Tie Q. Wei
-
Patent number: 7547518Abstract: Provided is a method of screening a primary endothelial cell population for angiogenesis capability comprising: (a) measuring the percentage of cells that are positive for VEGF R2 and CD34, the level of VEGF R2, or measuring the VEGF R2 to VEGF R1 ratio in the population; and (b) selecting those populations where the measured percentage or the measured ratio is over a threshold value.Type: GrantFiled: August 6, 2004Date of Patent: June 16, 2009Assignee: Becton, Dickinson and CompanyInventor: Min Wu
-
Patent number: 7544466Abstract: Ghrelin is acylated by ghrelin O-acyltransferase. Ghrelin O-acyltransferase assays comprise contacting a mixture of ghrelin and recombinant ghrelin O-acyltransferase with an agent; and detecting a resultant decrease in acylation of the ghrelin by the acyltransferase.Type: GrantFiled: December 29, 2007Date of Patent: June 9, 2009Assignee: Board of Regents, The University of Texas SystemInventors: Michael S. Brown, Joseph L. Goldstein, Nick V. Grishin, Jing Yang
-
Patent number: 7541160Abstract: The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA method and kits for VEGF as an antigen were developed to detect VEGF levels in biological samples from animal models and human patients and are used as a diagnostic/prognostic index.Type: GrantFiled: November 1, 2004Date of Patent: June 2, 2009Inventors: David Tai Wai Fei, Kristen Tomita
-
Patent number: 7527979Abstract: Assay systems and methods are provided for detecting a target pathogen, such as a microorganism (e.g., bacterium, bacterial toxin) which may be present in a fluid or other location. The method can include linking a magnetic microparticle to a first epitope of the target microorganism in a fluid via a first antibody; utilizing a magnetic field to separate the magnetic microparticle and linked targeted microorganism from at least a portion of other components in the fluid, thereby forming a test sample; linking a glucose molecule to a second epitope of the target microorganism via a second antibody; and detecting the glucose in the test sample to determine the presence or concentration of the target microorganism in the fluid. The glucose detection preferably is one that can be done rapidly, e.g., with a conventional glucometer, and may include measuring the electrical resistance, color, or pH of the test sample.Type: GrantFiled: August 16, 2005Date of Patent: May 5, 2009Assignee: Florida State University Research FoundationInventor: Yousef Haik
-
Patent number: 7527939Abstract: A specific and sensitive in vitro ELISA assay and diagnostic test kit is disclosed for determining levels of NT-proBNP protein in a variety of bodily fluids, non-limiting examples of which are blood, serum, plasma, urine and the like. The NT-proBNP ELISA assay test employs the sandwich ELISA technique to measure circulating NT-proBNP in human plasma. In order to obtain antibodies with specific binding properties for targeted amino acid sequences within human proBNP, recombinant human proBNP (or rhproBNP) was expressed and purified for use as an immunogen. Polyclonal antibodies (PAb) to specific amino acid sequences were subsequently purified from goat serum by sequential affinity purification. Monoclonal antibodies were raised against specific polypeptides. Recombinant human NT-proBNP (or rhNT-proBNP) was expressed and purified in order to obtain material for use in calibration of a quantitative method for measurement of human NT-proBNP.Type: GrantFiled: March 13, 2006Date of Patent: May 5, 2009Assignee: Nanogen, Inc.Inventors: Michelle Davey, George Jackowski, Peter Kupchak, Eric Stanton
-
Patent number: 7527980Abstract: Assay systems and methods are provided for detecting a target antigen in a physiological fluid (e.g., blood, serum, or urine). The method includes linking via a first antibody a magnetic microparticle to the target antigen in the physiological fluid; linking via a second antibody a glucose molecule to the target antigen; utilizing a magnetic field to separate the magnetic microparticle-linked antigen from the physiological fluid to form a test sample; and detecting the glucose in the test sample to determine the concentration of target antigen in the physiological fluid. The target antigen can be a protein or marker resulting from cardiac tissue injury, which can be used to assess acute myocardial infarction. An exemplary target antigen is myoglobin. The glucose detection preferably is one that can be done rapidly, e.g., with a conventional glucometer, and may include measuring the electrical resistance, color, or pH of the test sample.Type: GrantFiled: August 16, 2005Date of Patent: May 5, 2009Assignee: Florida State University Research FoundationInventor: Yousef Haik
-
Patent number: 7517701Abstract: Systems, including compositions, kits, and methods, particularly for photoluminescence applications. The systems may include, among others, (1) organic chelators, (2) complexes between the chelators and lanthanide ions, and (3) precursors, derivatives, and uses thereof. The chelators may include a 1,4,7,10-tetraazacyclododecane ring system, for example, having the formula: Here, R1, R2, and R3 are substituents of the tetraazacyclododecane ring system, that is further substituted at the 10-position by a sensitizer Z that is typically a polyheterocyclic ring system. The organic chelator may be capable of forming a luminescent complex with a lanthanide ion, and is optionally further substituted by a reactive functional group or a conjugated substance. The resulting lanthanide complex may be useful in luminescence-based assays, such as energy transfer assays, among others.Type: GrantFiled: October 14, 2005Date of Patent: April 14, 2009Assignee: MDS Analytical Technologies (US) Inc.Inventors: David Parker, Paul Atkinson, Filip Kielar, Annegret Boge, J. Richard Sportsman, Elizabeth Gaudet, George G. Yi
-
Publication number: 20090088337Abstract: Compositions and methods for Resonance Energy Transfer (RET) Based Detection of analyte binding are provided.Type: ApplicationFiled: October 17, 2008Publication date: April 2, 2009Inventors: Ronald Gill, Miles Brennan, Millard Gambrell Cull, Anthony West
-
Patent number: 7507550Abstract: The present invention concerns an immunological test for determining NT-proBNP comprising at least two antibodies to NT-proBNP, wherein at least one of the antibodies to NT-proBNP is a monoclonal antibody. One of these antibodies is directed at least against parts of the epitope of NT-proBNP comprising the amino acids 38 to 50. In addition, one of these antibodies is directed at least against parts of the epitope of NT-proBNP comprising the amino acids 1 to 37 or 43 to 76. The epitope recognized by the antibodies can slightly overlap.Type: GrantFiled: November 22, 2004Date of Patent: March 24, 2009Assignee: Roche Diagnostics Operations, Inc.Inventors: Juergen Spinke, Alfons Nichtl, Volker Klemt, Klaus Hallermayer, Michael Grol, Anneliese Borgya, Andreas Gallusser
-
Patent number: 7507585Abstract: The present invention describes methods and kits for determining the level of S-nitrosothiols in biological fluid samples. The method includes separating tissue or cellular matter from the biological fluid sample and then contacting the biological fluid sample with paraformaldehyde in an amount sufficient to fix free thiols thereby essentially eliminating diaphorase activity of the free thiols. The biological fluid sample is then contacted with NADPH and nitro blue tetrazolium (NBT) wherein S-nitrosothiols in the biological fluid sample facilitate the reduction of NBT to NBT formazan or diformazan in the presence of paraformaldehyde. The amount of reduced NBT is measured and the determined levels correlate to the amount of S-nitrosothiols in the biological fluid sample.Type: GrantFiled: January 10, 2005Date of Patent: March 24, 2009Inventor: Erin J. Whalen
-
Publication number: 20090010839Abstract: Dimers of avidin and streptavidins (diavidins) are described wherein the linker is suberate, which in turn, is bound to different functional groups (—NH2 o-COOH) of avidin. As compared to avidin, the diavidins have shown the ability to increase the amount of labelled biotin on the target, when used in an in vitro pretargeting test using supported human tenascin, the biotinylated anti-tenascin monoclonal antibody (Mab-B), avidin/diavidin, and biotin-3H. The use of such diavidins is also described in cancer diagnosis and anticancer therapy based on the three-step pretargeted radioimmunotherapy procedure.Type: ApplicationFiled: July 3, 2008Publication date: January 8, 2009Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHEInventors: De Santis Rita, Lindstedt Ragnar, Nuzzolo Carlo Antonio
-
Patent number: 7473564Abstract: The invention concerns a kit for the detection of protein ESM-1 in a sample, comprising: a) a first antibody specifically binding to the N-terminal region of protein ESM-1 contained between the amino acid in position 20 and the amino acid in position 78 of the amino acid sequence of this protein; and b) a second antibody specifically binding to the C-terminal region contained between the amino acid in position 79 and the amino acid in position 184 of the amino acid sequence of protein ESM-1.Type: GrantFiled: November 8, 2001Date of Patent: January 6, 2009Assignees: Institut Pasteur de Lille, Institut National de la Sante et de la Recherche MedicaleInventors: Philipp Lassalle, David Bechard, André-Bernard Tonnel
-
Patent number: 7473535Abstract: The invention provides a reagent comprising an affinity tag, a detectable moiety, a linker, an isotope tag and a reactive group. The invention also provides methods of using a reagent of the invention. The methods can be used to label a polypeptide in a sample by contacting a sample with a reagent of the invention under conditions allowing the reactive group to bind to one or more polypeptides in the sample. The invention additionally provides methods of isolating, identifying and quantifying a polypeptide in a sample. The invention further provides methods of diagnosing a disease using a reagent of the invention.Type: GrantFiled: August 20, 2002Date of Patent: January 6, 2009Assignees: The Institute for Systems Biology, University of WashingtonInventors: Rudolf H. Aebersold, Patricia Q. Bottari, Michael H. Gelb, Frantisek Turecek
-
Patent number: 7462462Abstract: It is intended to provide a peptide or a phage recognizing nanographite structures and thus enabling efficient recognition, binding, separation and alignment of nanographite structures such as carbon nanohorns or carbon nanotubes, an artificial protein or a chimeric molecule comprising the above-described peptide bonded to a functional peptide, a protein, a labeling, etc., and a complex of the above-described peptide molecule, artificial protein or chimeric molecule with a nanographite structure. By panning peptide-presenting phages bonded to nanographite structures, a nanographite structure-binding peptide capable of specifically recognizing nanographite structures such as carbon nanohorns or carbon nanotubes is obtained.Type: GrantFiled: April 4, 2005Date of Patent: December 9, 2008Assignees: Japanese Foundation For Cancer Research, NEC CorporationInventors: Kiyotaka Shiba, Daisuke Kase, Sumio Iijima